Improved Delivery Methods for Gene Therapy and Cell Transplantation in Parkinson's Disease

Overview

Journal J Parkinsons Dis

Publisher Sage Publications

Specialty Neurology

Date 2021 Aug 9

PMID 34366372

Citations 3

Authors

Paul S Larson

Affiliations

Soon will be listed here.

Abstract

A number of cell transplantation and gene therapy trials have been performed over the last three decades in an effort to restore function in Parkinson's disease. Much has been learned about optimizing delivery methods for these therapeutics. This is particularly true in gene therapy, which has predominated the clinical trial landscape in recent years; however, cell transplantation for Parkinson's disease is currently undergoing a renaissance. Innovations such as cannula design, iMRI-guided surgery and an evolution in delivery strategy has radically changed the way investigators approach clinical trial design. Future therapeutic strategies may employ newer delivery methods such as chronically implanted infusion devices and focal opening of the blood brain barrier with focused ultrasound.

Citing Articles

Advancements in surgical treatments for Huntington disease: From pallidotomy to experimental therapies.

Kim L, Kundu B, Moretti P, Lozano A, Rahimpour S Neurotherapeutics. 2024; 21(6):e00452.

PMID: 39304438 PMC: 11585891. DOI: 10.1016/j.neurot.2024.e00452.

Preclinical evaluation of transaxial intraputaminal trajectory for enhanced distribution of grafted cells in Parkinson's disease.

Emborg M, Mancinelli A, Colwell J, Zinnen A, Pape B, Brunner K J Neurosurg. 2024; 141(6):1554-1566.

PMID: 39059426 PMC: 11609033. DOI: 10.3171/2024.4.JNS24367.

Genetically engineered mesenchymal stem cells with dopamine synthesis for Parkinson's disease in animal models.

Li J, Li N, Wei J, Feng C, Chen Y, Chen T NPJ Parkinsons Dis. 2022; 8(1):175.

PMID: 36550118 PMC: 9780305. DOI: 10.1038/s41531-022-00440-6.

References

Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014; 270(3):834-41. DOI: 10.1148/radiol.13131669. View

Alarcon-Aris D, Pavia-Collado R, Miquel-Rio L, Coppola-Segovia V, Ferres-Coy A, Ruiz-Bronchal E . Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine. 2020; 59:102944. PMC: 7452525. DOI: 10.1016/j.ebiom.2020.102944. View

McMahon D, OReilly M, Hynynen K . Therapeutic Agent Delivery Across the Blood-Brain Barrier Using Focused Ultrasound. Annu Rev Biomed Eng. 2021; 23:89-113. DOI: 10.1146/annurev-bioeng-062117-121238. View

Marks Jr W, Ostrem J, Verhagen L, Starr P, Larson P, Bakay R . Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008; 7(5):400-8. DOI: 10.1016/S1474-4422(08)70065-6. View

Lindvall O, Widner H, Rehncrona S, Brundin P, Odin P, Gustavii B . Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol. 1992; 31(2):155-65. DOI: 10.1002/ana.410310206. View

Hadaczek P, Kohutnicka M, Krauze M, Bringas J, Pivirotto P, Cunningham J . Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther. 2006; 17(3):291-302. DOI: 10.1089/hum.2006.17.291. View

Drane D, Loring D, Voets N, Price M, Ojemann J, Willie J . Better object recognition and naming outcome with MRI-guided stereotactic laser amygdalohippocampotomy for temporal lobe epilepsy. Epilepsia. 2014; 56(1):101-13. PMC: 4446987. DOI: 10.1111/epi.12860. View

Richardson R, Bankiewicz K, Christine C, Van Laar A, Gross R, Lonser R . Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2020; 91(11):1210-1218. PMC: 7569395. DOI: 10.1136/jnnp-2020-322904. View

Bartus R, Baumann T, Siffert J, Herzog C, Alterman R, Boulis N . Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology. 2013; 80(18):1698-701. PMC: 3716474. DOI: 10.1212/WNL.0b013e3182904faa. View

10.

Olanow C, Goetz C, Kordower J, Stoessl A, Sossi V, Brin M . A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003; 54(3):403-14. DOI: 10.1002/ana.10720. View

11.

Olanow C, Koller W, Goetz C, Stebbins G, Cahill D, Gauger L . Autologous transplantation of adrenal medulla in Parkinson's disease. 18-month results. Arch Neurol. 1990; 47(12):1286-9. DOI: 10.1001/archneur.1990.00530120030006. View

12.

Yin D, Valles F, Fiandaca M, Bringas J, Gimenez F, Berger M . Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage. 2009; 54 Suppl 1:S196-203. PMC: 2895968. DOI: 10.1016/j.neuroimage.2009.08.069. View

13.

Bankiewicz K, Pasterski T, Kreatsoulas D, Onikijuk J, Mozgiel K, Munjal V . Use of a novel ball-joint guide array for magnetic resonance imaging-guided cannula placement and convective delivery: technical note. J Neurosurg. 2020; 135(2):651-657. DOI: 10.3171/2020.6.JNS201564. View

14.

Shukla N, Ho A, Pendharkar A, Sussman E, Halpern C . Laser interstitial thermal therapy for the treatment of epilepsy: evidence to date. Neuropsychiatr Dis Treat. 2017; 13:2469-2475. PMC: 5627747. DOI: 10.2147/NDT.S139544. View

15.

Whone A, Luz M, Boca M, Woolley M, Mooney L, Dharia S . Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. Brain. 2019; 142(3):512-525. PMC: 6391602. DOI: 10.1093/brain/awz023. View

16.

Sudhakar V, Mahmoodi A, Bringas J, Naidoo J, Kells A, Samaranch L . Development of a novel frameless skull-mounted ball-joint guide array for use in image-guided neurosurgery. J Neurosurg. 2019; 132(2):595-604. DOI: 10.3171/2018.10.JNS182169. View

17.

Richardson R, Kells A, Rosenbluth K, Salegio E, Fiandaca M, Larson P . Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther. 2011; 19(6):1048-57. PMC: 3129792. DOI: 10.1038/mt.2011.11. View

18.

Kanda T, Nakai Y, Oba H, Toyoda K, Kitajima K, Furui S . Gadolinium deposition in the brain. Magn Reson Imaging. 2016; 34(10):1346-1350. DOI: 10.1016/j.mri.2016.08.024. View

19.

Christine C, Bankiewicz K, Van Laar A, Richardson R, Ravina B, Kells A . Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. Ann Neurol. 2019; 85(5):704-714. PMC: 6593762. DOI: 10.1002/ana.25450. View

20.

Li W, Englund E, Widner H, Mattsson B, van Westen D, Latt J . Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci U S A. 2016; 113(23):6544-9. PMC: 4988567. DOI: 10.1073/pnas.1605245113. View